1
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Marc J Ostro, Micrea C Popescu: Stable plurilamellar vesicles, their preparation and use. The Liposome Company, Pennie & Edmonds, June 11, 1985: US04522803 (204 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.


2
Mircea C Popescu, Paul A Tremblay, Andrew S Janoff, Marc J Ostro, Elaine Chan, Alan Weiner: Pharmacological agent-lipid solution preparation. The Liposome Company, Allen Bloom, Ilene Janofsky, October 13, 1992: US05154930 (72 worldwide citation)

A pharmacological agent-lipid solution preparation comprising a lipophilic pharmacological agent, a desalted charged lipid and an aqueous-miscible lipid solvent such that upon introduction into an aqueous medium a suspension of lipid aggregates associated with the pharmacological agent are formed, a ...


3
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Ronald G Ort, December 8, 1992: US05169637 (71 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


4
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Thomas M Saunders, Ronald G Ort, July 9, 1991: US05030453 (68 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


5
Andrew S Janoff, Mircea C Popescu, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Catherine L Kurtz, October 22, 1991: US05059591 (49 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


6
Andrew S Janoff, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Mircea C Popescu, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Thomas M Saunders, January 30, 1990: US04897384 (34 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


7
Andrew S Janoff, Marc J Ostro, Alan L Weiner, Gerald Weissmann, James R Seibold: Liposome composition for lupus assay. The Liposome Company, Pennie & Edmonds, May 26, 1987: US04668638 (24 worldwide citation)

An immunoassay utilizing a novel liposome composition in which there is incorporated a stabilizing or destabilizing component and an antigen. The presence of cognate antibodies in test samples is detected by the alteration of the supramolecular structure of the liposomes resulting in changes in stab ...


8
Andrew S Janoff, Marc J Ostro, Alan L Weiner, Gerald Weissmann, James R Seibold: Liposome composition for lupus assay. The Liposome Company, Pennie & Edmonds, January 14, 1986: US04564599 (23 worldwide citation)

An assay for detecting SLE antibodies utilizing a novel liposome composition in which there is entrapped a divalent cation responsive indicator. The presence of such antibodies is detected by their stabilization of the supermolecular structure of the liposomes. Such stabilization can be detected, an ...


9
Robert P Lenk, Michelle L Tomsho, Robert L Suddith, Robert J Klimchak, Andrew S Janoff, Sharma R Minchey, Marc J Ostro: Therapeutic use of multilamellar liposomal prostaglandin formulations. The Liposome Company, Kenneth Rubin, Rosanne Goodman, July 20, 1999: US05925375 (8 worldwide citation)

This invention provides a multilamellar liposome containing an arachidonic acid metabolite, two or more lipid-containing bilayers and two or more aqueous compartments containing a release-inhibiting buffer. Preferred arachidonic acid metabolites are the prostaglandins, particularly PGE.sub.1. The li ...


10
Marc J Ostro, Andrew S Janoff, Sharma R Minchey: Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, September 22, 1998: US05811118 (5 worldwide citation)

This invention provides a method of administering an arachidonic acid metabolite, such as prostaglandin E1, to an animal. The metabolite is given to the animal, typically a human, in association with a unilamellar liposome comprising a lipid and a release-inhibiting aqueous buffer. This method can b ...